Tendon Medic™

Plasma collected from volunteers after oral Pycnogenol® supplementation inhibited COX-1 and COX-2 activity in laboratory assays. These enzymes participate in the production of prostaglandins involved in inflammatory responses.

Following short-term Pycnogenol® supplementation, researchers observed reduced COX-2 and 5-LOX gene expression, reduced phospholipase A2 activity, and reduced leukotriene production in white blood cells tested under an inflammatory challenge.

Plasma collected after Pycnogenol® supplementation reduced MMP-9 release and NF-κB activation in human-monocyte laboratory assays. MMP-9 participates in extracellular-matrix breakdown, while NF-κB helps regulate inflammatory gene expression.

Laboratory research investigated a standardized Devil’s Claw extract’s effects on inflammatory mediators and signaling, including TNF-α, COX-2 expression, and AP-1. These findings provide a mechanism-based rationale for inclusion, not proof of the same effects in people taking Tendon Medic.

A 12-week uncontrolled study involving 75 adults with hip or knee osteoarthritis reported improvements in pain, stiffness, and physical function with a particular aqueous Devil’s Claw extract. Because the study lacked a placebo group, it cannot establish how much improvement was caused by the treatment.

A four-month randomized, double-blind trial involving 122 adults with knee or hip osteoarthritis compared a specific Devil’s Claw preparation with diacerein. Both groups showed improvements in pain and function. The Devil’s Claw group used less additional pain medication and reported fewer adverse events.

A systematic review evaluated Devil’s Claw preparations for osteoarthritis and low-back pain. Findings depended on the preparation and daily dose studied; they should not be presented as proof that every Devil’s Claw extract produces equivalent results.

A human pilot crossover study reported approximately 6.93-fold greater relative bioavailability for BCM-95® than conventional curcumin and approximately 6.3-fold greater than the specific curcumin–lecithin–piperine formulation tested. These comparisons measured blood exposure, not pain relief or therapeutic equivalence.

In a rat model of surgically repaired Achilles tendon injury, short-term oral curcumin treatment reduced adhesions—scar-like tissue that can bind a healing tendon to surrounding tissues. Researchers also reported improved collagen organization and structural and biomechanical healing measures. These findings suggest potential for curcumin in tendon recovery, but do not establish effectiveness for human tendinitis or for BCM-95® specifically.

A review examined curcumin’s anti-inflammatory effects across multiple conditions and experimental settings, including its regulation of inflammatory mediators and signaling pathways. It provides background on curcumin’s mechanisms, rather than evidence that this 250 mg BCM-95® serving lowers TNF-α, IL-6, and CRP in people with tendon discomfort.

In cultured human cartilage cells and cartilage explants, curcumin reduced production of MMP-3 and inflammatory mediators, including prostaglandin E₂, IL-6, and IL-8, in a concentration-dependent manner. This was laboratory research, not an oral BCM-95® trial or evidence of cartilage regeneration in people.

A scoping review of 50 original studies examined curcumin in osteoarthritis using cell, animal, and human research. It summarized findings involving matrix metalloproteinases, cartilage-cell survival, collagen-related responses, and signaling pathways such as NF-κB and AMPK/PINK1/Parkin. These findings support further investigation; they do not establish the same effects for every curcumin formulation or dose.

In a randomized, double-blind trial involving 78 adults with hip or knee osteoarthritis, a standardized willow bark extract supplying 240 mg of salicin daily produced a moderate pain-relieving effect over two weeks. WOMAC pain scores decreased 14% from baseline, compared with a 2% increase in the placebo group. The between-group difference was statistically significant.

A systematic review found moderate evidence supporting certain ethanolic willow bark extracts for short-term low-back pain relief. Included studies suggested a dose-dependent effect and reported comparisons with rofecoxib. Findings for osteoarthritis were conflicting. These results apply to the preparations and doses studied, rather than establishing equivalence to prescription NSAIDs generally.

A meta-analysis included five studies reporting six randomized controlled trials, with 329 participants. Pooled results favored willow-bark-containing treatments for overall pain and WOMAC scores, but the evidence was rated very low certainty. Some trials tested multi-ingredient combinations, and separate analyses did not show significant improvements in stiffness or physical function.

Researchers tested willow bark extracts for effects on cyclooxygenase enzymes and inflammatory mediator release. Certain extracts inhibited COX-1 and COX-2 activity and reduced prostaglandin E₂ release from stimulated human immune cells. These enzymes participate in prostaglandin production, connecting the findings to a pathway involved in pain and inflammation. Activity depended on extraction method and composition; the water extract did not show the same enzyme inhibition as the methanol-containing extracts tested.

A standardized willow bark extract reduced prostaglandins, leukotrienes, and other inflammatory measures in rat models of acute and chronic inflammation. Leukotrienes are produced through a pathway involving 5-lipoxygenase, or 5-LOX. Their reduction provides a connection to this pathway, but does not by itself establish direct inhibition of the 5-LOX enzyme. The researchers concluded that constituents beyond salicin likely contributed to the extract’s activity.

A laboratory study compared rosehip, white willow bark, and nettle leaf extracts in canine cartilage cells exposed to the inflammatory cytokine IL-1β. In the separately tested willow-bark group, researchers observed suppression of NF-κB signaling and reduced expression of COX-2, MMP-9, and MMP-13. These findings provide preliminary evidence involving inflammatory signaling and matrix-degrading enzyme expression—not demonstrated tendon protection or cartilage repair in people.

A systematic review and meta-analysis included seven randomized controlled trials involving 545 participants with osteoarthritis. Pooled findings favored Boswellia-containing treatments for pain, stiffness, and joint function. However, formulations varied, several studies tested combinations, and substantial differences between studies and risks of bias limit confidence in the results.

A 90-day randomized, double-blind, multicenter trial enrolled 105 adults with knee osteoarthritis and tested Boswellin® Super, standardized to 30% AKBA, at 150 mg or 300 mg twice daily. Participants receiving the extract showed improvements in pain and function over the study.

The authors reported changes as early as day five, but the principal pain and total WOMAC comparisons were not statistically different from placebo at that time; significant between-group differences were reported at days 60 and 90. The study involved manufacturer-affiliated authors and should be identified as research on that specific extract.

Distinction: Tendon Medic uses a different Boswellia extract, not Boswellin® Super. Although both are standardized to 30% AKBA, matching that percentage alone does not establish equivalent composition, absorption, or clinical effects. This study provides related Boswellia research, not demonstrated results for the extract in Tendon Medic.

A 90-day randomized, double-blind, placebo-controlled trial enrolled 75 adults with knee osteoarthritis; 70 completed the study. Researchers tested 5-Loxin®, a Boswellia extract standardized to 30% AKBA, at 100 mg or 250 mg daily. Both treatment groups showed improvements in pain and selected measures of physical function. In the participants with joint-fluid measurements, MMP-3 concentrations were approximately 31% and 46% lower than placebo in the lower- and higher-dose groups, respectively. This measured enzyme concentration, not cartilage regeneration.

Tendon Medic uses a different Boswellia extract, not 5-Loxin®. This study provides related ingredient research, not demonstrated results for the extract in this formula.

Researchers demonstrated that AKBA inhibited 5-lipoxygenase in cell-based and cell-free experiments. The study examined how AKBA’s chemical structure affected binding and inhibitory activity, providing direct enzyme-level evidence for Boswellia’s 5-LOX rationale. Laboratory concentrations do not establish the degree of inhibition achieved after oral supplementation.

Research on Boswellia preparations found reduced production of leukotrienes and other 5-LOX products in stimulated human immune cells. Findings also supported an AKBA-associated shift in the products generated by 5-LOX, suggesting modulation of enzyme activity rather than simply switching the pathway off. Effects varied among preparations with different boswellic-acid compositions.

The Boswellin® Super trial also measured circulating TNF-α, IL-6, and high-sensitivity CRP and reported reductions in participants receiving the extract over 90 days. These are inflammatory markers—not enzymes—and provide a separate clinical observation alongside the pain and mobility findings. They do not establish that the same changes occur with every 30%-AKBA extract.

In cultured human tenocytes exposed to IL-1β, resveratrol reduced inflammatory signaling and apoptosis, or programmed cell death. It also counteracted suppression of collagen types I and III, tenomodulin, and scleraxis. These findings connect resveratrol directly to tendon-cell responses under an experimental inflammatory challenge—not to proven tendon regeneration in people.

The same tenocyte study investigated how resveratrol affected the enzyme-signaling machinery upstream of NF-κB. Researchers reported reduced PI3K and NF-κB activation, effects involving IκB kinase signaling, and a role for SIRT1-mediated regulation. This provides an enzyme-focused explanation for the observed cellular effects, rather than treating resveratrol simply as a general antioxidant.

A critical narrative review summarized experimental findings involving resveratrol and MMP-1, MMP-3, and MMP-13 expression in cartilage and joint-associated cells. It also discussed COX-related signaling and animal arthritis studies reporting reduced inflammatory mediators, cartilage damage, or bone erosion. Results varied by model, concentration, and route of administration; some animal experiments used injections directly into the joint.

Researchers cultured synovial-fluid mononuclear cells from seven people with rheumatoid arthritis and seven with spondyloarthritis. Resveratrol significantly reduced MCP-1, a chemokine involved in immune-cell recruitment. It did not significantly change MMP-3 production or tartrate-resistant acid phosphatase activity, the study’s marker of osteoclast differentiation. This supports an anti-inflammatory finding without claiming enzyme or bone-resorption effects that the experiment did not demonstrate.

A laboratory study tested resveratrol individually and in combination with vitamin C, collagen peptides, and astaxanthin in human tenocytes. The combination reduced inflammatory IL-6 release, MMP-2 secretion, NF-κB nuclear translocation, and oxidative-stress measures. These findings concern the specific experimental combination; they should not be attributed to resveratrol alone or presented as proof of synergy in Tendon Medic.

A meta-analysis of five randomized placebo-controlled trials involving 593 adults with osteoarthritis found statistically significant, modest reductions in pain and disability with oral ginger. The authors rated the evidence moderate quality. Participants taking ginger were also more likely to discontinue because of adverse events than those taking placebo.

A scientific review summarizes research showing that ginger can suppress prostaglandin synthesis through inhibition of COX-1 and COX-2, and suppress leukotriene synthesis through inhibition of 5-LOX. These findings connect ginger to both branches of the arachidonic-acid inflammatory cascade. Activity depends on the preparation and experimental conditions.

The same review describes an extract derived from ginger and Alpinia galanga that inhibited induction of inflammatory genes, including those encoding cytokines, chemokines, and COX-2. This adds an enzyme-expression mechanism alongside the enzyme-activity findings. The mixed botanical preparation should not be represented as identical to this ginger ingredient.

A meta-analysis of 16 randomized controlled trials involving 1,010 participants found significant pooled reductions in CRP, hs-CRP, and TNF-α following ginger supplementation. It did not find significant overall effects on IL-6 or soluble ICAM. Results varied substantially between studies, and these circulating markers are not direct measurements of tendon inflammation or enzyme inhibition.

In cultured human intestinal cells, ginger extract inhibited P-glycoprotein activity in a transporter assay and increased transport of tested soy isoflavones. P-glycoprotein is not specific to those nutrients, so the transporter finding provides a broader mechanism worth investigating. Whether ginger improves absorption of other compounds depends on the compound and preparation; the study did not test the complete Tendon Medic formula.

Researchers studied oral bromelain in 19 healthy men and detected intact bromelain in plasma, with biological activity retained at least in part. Circulating bromelain was associated with the blood antiproteases alpha-2-macroglobulin and alpha-1-antichymotrypsin. The authors described the intestinal transport as small but significant—not evidence that most of an oral dose enters circulation.

A review evaluated systemic enzyme therapy in rheumatic disorders, primarily involving combinations of bromelain, papain, trypsin, and chymotrypsin. Some placebo-controlled studies and comparisons with NSAIDs suggested analgesic and anti-inflammatory effects, but results were inconsistent. The authors identified possible roles for proteinase–antiproteinase interactions and immune signaling, while emphasizing that the precise mechanism remained unresolved.

A bromelain review summarizes experimental findings involving increased conversion of plasminogen to plasmin, an enzyme that breaks down fibrin. This connects bromelain to the body’s fibrinolytic machinery. It does not establish that oral bromelain removes tendon adhesions, reverses fibrosis, or selectively breaks down unwanted tissue in people.

The same review describes reduced COX-2 expression and prostaglandin E₂ production in experimental cell models. These findings connect bromelain to the arachidonic-acid inflammatory cascade, but they are not equivalent to demonstrating direct COX inhibition or the same mechanism as an NSAID.

Bromelain research includes effects involving the kallikrein–kinin system, which participates in bradykinin generation and inflammatory swelling. Reviews describe anti-edematous activity and proposed effects on this pathway. These findings add a swelling-related mechanism beyond COX signaling, without establishing the magnitude of benefit from this formula.

A review describes a randomized clinical study in which bromelain was used alongside standard treatment following third-molar surgery. Reported benefits included reduced postoperative inflammation and swelling. This provides evidence in a surgical-recovery setting, not direct evidence of tendon healing or equivalent results from a different enzyme blend.

Bromelain reviews describe increased concentrations of certain antibiotics when administered with bromelain. These findings suggest compound-specific effects on drug exposure; they do not establish improved absorption of every nutrient or botanical in Tendon Medic. Such effects also warrant medication-interaction review.